Ascendis Pharma A/S has published a document on the clinical results for combination therapy with TransCon CNP and TransCon hGH in children with achondroplasia. The document provides data on annualized growth velocity, height Z-score changes, body proportionality, and safety outcomes, including adverse events. The results include information on efficacy and tolerability observed over 52 weeks of treatment. The full document can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.